Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug aims to boost immune attack on aggressive brain tumors

NCT ID NCT07301268

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells inside the tumor and shrink it, making surgery more effective. About 36 adults will take part, and researchers will measure changes in the tumor's immune environment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GI-102 (a bispecific fusion protein) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, potentially improving immune response against the tumor.
What could go wrong
This is a small, early-phase trial (36 participants) focused on immune changes, not yet on survival or cure. The drugs may not work or could cause side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) astrocytoma, IDH-mutant, grade 4 glioblastoma gliosarcoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE PROGRESSIVE ASTROCYTOMA, IDH-MUTANT, GRADE 4 PROGRESSIVE GLIOBLASTOMA PROGRESSIVE GLIOSARCOMA RECURRENT ASTROCYTOMA, IDH-MUTANT, GRADE 4 RECURRENT GLIOBLASTOMA, IDH-WILDTYPE RECURRENT GLIOSARCOMA RESECTABLE ASTROCYTOMA RESECTABLE GLIOBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.